**Supplemental Table 1: TOTAL STUDY POPULATION**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variables** | **S0**  **CAP < 238 dB/m**  **(n=215)** | **S1**  **CAP 238-259 dB/m**  **(n=43)** | **S2**  **CAP 260-291 dB/m**  **(n=51)** | **S3**  **CAP > 291 dB/m**  **(n=55)** | **p-value** |
| Age (range) - yr | 43 (20-75) | 48 (30-73) | 47 (25-74) | 50 (30-74) | **0.000** |
| Male gender (no. %) | 159 (74) | 34 (79) | 40 (78) | 52 (95) | **0.008** |
| Caucasian (no. %) | 150 (70) | 36 (84) | 43 (84) | 49 (89) | **0.004** |
| Time since HIV positive (range) - yr | 7 (0-29) | 11 (0-28) | 9 (0-29) | 11 (0-28) | **0.031** |
| Time cART naive (range) - yr | 1 (0-20) | 2 (0-17) | 1 (0-18) | 0 (0-21) | **0.037** |
| BMI (range) - kg/m2 | 23 (15-41) | 25 (19-29) | 25 (20-36) | 28 (19-38) | **0.000** |
| Cholesterol (range) - mg/dl | 185 (72-342) | 195 (88-304) | 195 (101-284) | 212 (121-290) | **0.001** |
| HDL (range) - mg/dl | 48 (8-127) | 45 (23-94) | 46 (25-100) | 37 (18-74) | **0.002** |
| LDL (range) - mg/dl | 113 (42-210) | 115 (41-185) | 111 (41-199) | 129 (57-203) | **0.044** |
| Triglycerides (range) - mg/dl | 120 (28-1549) | 119 (53-737) | 161 (55-1150) | 214 (43-1193) | **0.000** |
| ALT/GPT (range) - U/l | 29 (8-161) | 30 (17-78) | 35 (16-90) | 36 (20-151) | **0.003** |
| GGT (range) - U/l | 40 (12-340) | 45 (22-295) | 54 (20-333) | 49 (22-568) | **0.002** |
| HbA1c (range) - % | 5.3 (2.7-8.1) | 5.3 (3.6-7.4) | 5.3 (4.6-7.9) | 5.5 (3.8-11.4) | **0.015** |
| DM 2 (no. %) | 6 (3) | 1 (2) | 2 (4) | 7 (13) | **0.012** |
| - on antidiabetics (no. %) | 4 (67) | 1 (100) | 1 (50) | 5 (71) | **0.043** |
| LPVr history (no.%) | 56 (26) | 16 (40) | 13 (26) | 26 (48) | **0.019** |

Baseline subject characteristics. overall and by significant hepatic steatosis as determined by CAP **≥** 238 kPa. Data are shown as median (IQR) or n (%).

**Supplemental Table 2: HIV MONO-INFECTED POPULATION**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variables** | **All subjects**  **(n=289)** | **S0 CAP ≤ 237 dB/m**  **(n=171)** | **S1 CAP 238-259 dB/m**  **(n=34)** | **S2 CAP 260-291 dB/m**  **(n=38)** | **S3 CAP ≥ 292 dB/m**  **(n=46)** | **p-value** |
| Nadir CD4 cells (range) - cells/mm3 | 245 (0-947) | 246 (0-947) | 234 (5-728) | 254 (11-640) | 233 (11-793) | 0.886 |
| Nadir CD4 cells (range) - % | 18 (0-51) | 18 (0-49) | 17 (0-39) | 18 (2-51) | 17 (1-41) | 0.771 |
| CD4 cells (range) - cells/mm3 | 548 (29-1478) | 529 (37-1478) | 548 (150-980) | 528 (29-1268) | 630 (212-1197) | 0.075 |
| CD8 cells (range) - cells/mm3 | 837 (124-2498) | 818 (124-2408) | 877 (263-2498) | 800 (277-2153) | 903 (314-2264) | 0.586 |
| CD4/CD8 ratio (range) | 0.8 (0.1-2.7) | 0.7 (0.1-2.0) | 0.8 (0.1-2.7) | 0.8 (0.2-2.2) | 0.8 (0.2-1.5) | 0.752 |
| Platelet count (range) - U/l | 225 (61-494) | 229 (61-494) | 232 (128-433) | 215 (126-408) | 213 (108-312) | 0.207 |
| Albumin (range) - g/dl | 44 (22-54) | 44 (22-53) | 45 (36-52) | 45 (38-54) | 45 (41-51) | 0.862 |
| CRP (range) - mg/dl | 4.1 (0.2-30.9) | 4.2 (0.2-30.9) | 1.7 (0.5-3.8) | 2.6 (0.7-5.7) | 5.4 (0.7-18.5) | 0.621 |
| MSM (no. %) | 161 (56) | 89 (52) | 22 (65) | 22 (58) | 28 (61) | 0.455 |
| IDU (no. %) | 3 (1) | 2 (1) | 0 (0) | 1 (3) | 0 (0) | 0.613 |
| Statins intake (no. %) | 25 (9) | 13 (8) | 2 (6) | 5 (13) | 5 (11) | 0.608 |
| Nadir CD4 < 200 cells/mm3 (no. %) | 128 (44) | 72 (42) | 17 (50) | 16 (42) | 23 (50) | 0.691 |
| CDC-C (no. %) | 76 (26) | 39 (23) | 9 (27) | 11 (29) | 17 (37) | 0.271 |
| Naive (no. %) | 18 (6) | 13 (8) | 2 (6) | 3 (8) | 0 (0) | 0.284 |
| Detectable HIV viremia > 40 c/mL (no.%) | 50 (17) | 35 (21) | 6 (18) | 5 (13) | 4 (9) | 0.266 |
| HIV viremia 40 – 200 c/mL (no.%) | 14 (5) | 9 (5) | 2 (6) | 2 (5) | 1 (2) | 0.833 |
| AZT history (no.%) | 77 (27) | 46 (27) | 9 (30) | 7 (19) | 15 (33) | 0.909 |
| d4T history (no.%) | 52 (18) | 27 (16) | 8 (24) | 6 (16) | 11 (24) | 0.219 |
| ddI history (no.%) | 20 (7) | 13 (8) | 1 (3) | 3 (8) | 3 (7) | 0.632 |

Baseline subject characteristics. overall and by significant hepatic steatosis as determined by CAP **≥** 238 kPa. Data are shown as median (IQR) or n (%).

**Supplemental Table 3: Association of CAP with variables in the total cohort.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **CAP** | | |
| **R** | **P** | **N** |
| **Correlations** | **Body weight** | **0.482** | **0.0001** | **356** |
| **BMI** | **0.500** | **0.0001** | **344** |
| **Triglycerides** | **0.305** | **0.0001** | **345** |
| **Age** | **0.296** | **0.0001** | **364** |
| **FIB4** | **0.232** | **0.0001** | **282** |
| **Cholesterol** | **0.217** | **0.0001** | **346** |
| **Trends** | LDL | 0.182 | **0.002** | 277 |
| HDL | -0.164 | **0.006** | 278 |
| HbA1c | 0.182 | **0.002** | 275 |
| GGT | 0.163 | **0.002** | 345 |
| GPT | 0.140 | **0.009** | 350 |
| HIV PCR | -0.134 | **0.014** | 336 |
| Time since HIV diagnosis | 0.129 | **0.014** | 364 |
| APRI | 0.128 | **0.031** | 282 |
| Cumulative cART duration | 0.127 | **0.018** | 346 |
| Transient elastography | 0.103 | **0.050** | 364 |

Correlations of patient characteristics and clinical parameters with HS assessed by CAP measurement.

**Supplemental Table 4:** **Logistic regression of overall multivariable analysis for CAP ≥ 238 dB/m in the total study population**.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Multivariable** | | |
| p-value | Odds ratio | 95% Confidence interval of odds ratio |
| Age | 0.031 | 1.035 | 1.003-1.067 |
| BMI | 0.000 | 1.239 | 1.123-1.366 |
| HDL | 0.015 | 0.976 | 0.957-0.995 |
| HbA1c | 0.056 | 1.498 | 0.989-2.269 |